Journal
CLINICAL GENITOURINARY CANCER
Volume 10, Issue 2, Pages 77-83Publisher
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clgc.2012.01.010
Keywords
Angiogenesis; Cell signaling; Renal cell carcinoma; Vascular endothelial growth factor receptor
Categories
Funding
- Novartis Pharmaceuticals
Ask authors/readers for more resources
Therapeutic inhibition of pathways involved in angiogenesis has become the standard of care in renal cell carcinoma (RCC). Most currently available antiangiogenic agents inhibit the vascular endothelial growth factor (VEGF) pathway. Although these drugs have produced exciting benefits, some tumors do not respond to these agents. In addition most if not all tumors that initially respond will eventually develop resistance. Tumor escape from antiangiogenic therapy may include various signaling pathways that are involved in angiogenesis, including the fibroblast growth factor (FGF) signaling pathway. Emerging preclinical data suggest that FGF and VEGF act distinctly and synergistically to promote tumor vascularization. The current review discusses the role of FGF signaling in resistance to anti-VEGF therapies and outlines potential therapeutic implications. Clinical Genitourinary Cancer, Vol. 10, No. 2, 77-83 (c) 2012 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available